Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet Lond Engl 379:432–444

Article  Google Scholar 

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242

Article  CAS  PubMed  Google Scholar 

Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS (2009) Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361:1249–1259

Article  CAS  PubMed  PubMed Central  Google Scholar 

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk, Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2023) Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet Lond Engl 401:1277–1292

Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, Cipolla CM (2016) Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin 66:309–325

PubMed  Google Scholar 

Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhães A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr 27:911–939

Article  Google Scholar 

Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH, ESC Scientific Document Group (2022) 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS). Eur Heart J 43:4229–4361

Article  PubMed  Google Scholar 

Rashed ER, Margulies KB (2023) New cardiotoxicity risk assessment guidelines: searching for validation. JACC CardioOncology 5:638–640

Article  PubMed  PubMed Central  Google Scholar 

Butel-Simoes LE, Ngo DTM, Sverdlov AL (2025) Navigating cardiotoxicity risk in cancer therapy: the importance of the HFA-ICOS score. Eur Heart J 46:285–287

Article  CAS  PubMed  Google Scholar 

Gomes C, Geels J, Debray TPA, Malekzadeh A, Asselbergs FW, Linschoten M (2025) Risk prediction models for cancer therapy related cardiac dysfunction in patients with cancer and cancer survivors: systematic review and meta-analysis. BMJ 390:e084062

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rivero-Santana B, Saldaña-García J, Caro-Codón J, Zamora P, Moliner P, Martínez Monzonis A, Zatarain E, Álvarez-Ortega C, Gómez-Prieto P, Pernas S, Rodriguez I, Buño Soto A, Cadenas R, Palacios Ozores P, Pérez Ramírez S, Merino Salvador M, Valbuena S, Fernández Gasso L, Juárez V, Severo A, Terol B, de Soto Álvarez T, Rodríguez O, Brion M, González-Costello J, Canales Albendea M, González-Juanatey JR, Moreno R, López-Sendón J, López-Fernández T (2025) Anthracycline-induced cardiovascular toxicity: validation of the heart failure association and international Cardio-Oncology society risk score. Eur Heart J 46:273–284

Article  CAS  PubMed  Google Scholar 

Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869–2879

Article  CAS  PubMed  Google Scholar 

Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr 28:1–39e14

Article  Google Scholar 

Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker MS, von Haehling S, Maack C, Pudil R, Barac A, Thavendiranathan P, Ky B, Neilan TG, Belenkov Y, Rosen SD, Iakobishvili Z, Sverdlov AL, Hajjar LA, Macedo AVS, Manisty C, Ciardiello F, Farmakis D, de Boer RA, Skouri H, Suter TM, Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF, Wechelaker A, Mauro MJ, Milojkovic D, de Lavallade H, Ruschitzka F, Coats AJS, Seferovic PM, Chioncel O, Thum T, Bauersachs J, Andres MS, Wright DJ, López-Fernández T, Plummer C, Lenihan D (2020) Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the cardio-oncology study group of the heart failure association of the European society of cardiology in collaboration with the international cardio-oncology society. Eur J Heart Fail 22:1945–1960

Article  PubMed  Google Scholar 

Kanda Y (2013) Investigation of the freely available easy-to-use software EZR for medical statistics. Bone Marrow Transpl 48:452–458

Article  CAS  Google Scholar 

Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, D’Ascenzo F, Malavasi V, Peruzzi M, Frati G, Palazzoni G (2013) Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol 112:1980–1984

Article  CAS  PubMed  Google Scholar 

Gent DG, Rebecca D (2023) The 2022 European society of cardiology Cardio-oncology guidelines in focus. Eur Cardiol Rev 18:e16

Article  Google Scholar 

Zheng H, Zhan H (2024) Preventing Anthracycline-Associated heart failure: what is the role of dexrazoxane? JACC CardioOncology 6:318–321

Article  PubMed  PubMed Central  Google Scholar 

Chavez-MacGregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, Smith BD, Hortobagyi GN, Giordano SH (2013) Trastuzumab-Related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31:4222–4228

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, Habel LA, Yood MU, McCarty C, Magid DJ, Wagner EH (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. JNCI J Natl Cancer Inst 104:1293–1305

Article  CAS  PubMed  Google Scholar 

Zhang J, Quan Y, Wang X, Wei X, Shen X, Li X, Liang T (2025) Global epidemiological characteristics of malnutrition in cancer patients: a comprehensive meta-analysis and systematic review. BMC Cancer 25:1191

Article  PubMed  PubMed Central  Google Scholar 

Stauder R, Augschoell J, Hamaker ME, Koinig KA (2020) Malnutrition in older patients with hematological malignancies at initial diagnosis—association with impairments in health status. Syst Inflamm Adverse Outcome HemaSphere 4:e332

Google Scholar 

Qiu S, Zhou T, Qiu B, Zhang Y, Zhou Y, Yu H, Zhang J, Liu L, Yuan L, Yang G, Duan Y, Xing C (2021) Risk factors for anthracycline-induced cardiotoxicity. Front Cardiovasc Med 8:736854

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koulaouzidis G, Yung AE, Yung DE, Skonieczna-Żydecka K, Marlicz W, Koulaouzidis A, Charisopoulou D (2021) Conventional cardiac risk factors associated with trastuzumab-induced cardiotoxicity in breast cancer: systematic review and meta-analysis. Curr Probl Cancer 45:100723

Article  PubMed  Google Scholar 

Russo G, Cioffi G, Di Lenarda A, Tuccia F, Bovelli D, Di Tano G, Alunni G, Gori S, Faggiano P, Tarantini L (2012) Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer. Intern Emerg Med 7:439–446

Article  PubMed  Google Scholar 

Camilli M, Cipolla CM, Dent S, Minotti G, Cardinale DM (2024) Anthracycline cardiotoxicity in adult cancer patients: JACC: cardiooncology State-of-the-Art review. JACC CardioOncol 6:655–677

Article  PubMed  PubMed Central  Google Scholar 

Rahman AM, Yusuf SW, Ewer MS (2007) Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomed 2:567–583

CAS  Google Scholar 

Shibata T, Nohara S, Morikawa N, Shibao K, Ito S, Shibata R, Toh U, Nagafuji K, Fukami K, Fukumoto Y (2023) Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO registry insights. Eur J Prev Cardiol 30:1941–1949

Article  PubMed  Google Scholar 

Larsen CM, Garcia Arango M, Dasari H, Arciniegas Calle M, Adjei E, Rico Mesa J, Scott CG, Thompson CA, Cerhan JR, Haddad TC, Goetz MP, Herrmann J, Villarraga HR (2023) Association of anthracycline with heart failure in patients treated for breast cancer or Lymphoma, 1985–2010. JAMA Netw Open 6:e2254669

Article  PubMed  PubMed Central  Google Scholar 

Seymour JF, Pfreundschuh M, Trnĕný M, Sehn LH, Catalano J, Csinady E, Moore N, Coiffier B (2014) R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica 99:1343–1349

Article